ACAD ACADIA PHARMACEUTICALS INC
Q3 2025 10-Q
ACADIA PHARMACEUTICALS INC (ACAD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New regulatory risk: January 2025 EU HTA Regulation No 2021/2282 requires joint clinical assessments impacting trofinetide pricing and reimbursement
- • Updated product acceptance risk: DAYBUE approved October 2024 in Canada; reliance on patient adherence and physician prescribing for Rett syndrome sales
Quarterly Financial SummaryXBRL
Revenue
$279M
Net Income
$72M
Operating Margin
12.8%
Net Margin
25.8%
ROE
7.8%
Total Assets
$1.3B
Source: XBRL data from ACADIA PHARMACEUTICALS INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ACADIA PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.